This HTML5 document contains 195 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
n11http://dx.doi.org/10.1158/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q35264283
rdf:type
wikibase:Item
schema:description
2015年論文 научни чланак 2015年の論文 article científic 2015年論文 teaduslik artikkel bilimsel makale 2015 թվականի փետրվարին հրատարակված գիտական հոդված vědecký článek artigo científico مقالة علمية artigo científico (publicado na 2015) научная статья 2015年论文 บทความทางวิทยาศาสตร์ 2015年論文 מאמר מדעי мақолаи илмӣ naučni članak 2015年论文 سائنسی مضمون artículu científicu espublizáu en 2015 artikull shkencor scientific article наукова стаття, опублікована в лютому 2015 artículo científico publicado en 2015 2015년 논문 2015年论文 научни чланак ২০১৫-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ article scientific 2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած tieteellinen artikkeli artigo científico (publicado na 2015) 2015年論文 2015年論文 επιστημονικό άρθρο videnskabelig artikel (udgivet 2015) vitskapeleg artikkel 2015 nî lūn-bûn wissenschaftlicher Artikel 2015年论文 научна статия articolo scientifico artikulong pang-agham мақолаи илмӣ 2015年论文 مقالهٔ علمی vedecký článok სამეცნიერო სტატია vetenskaplig artikel vitenskapelig artikkel articol științific 2015年论文 tudományos cikk artykuł naukowy article scientifique (publié 2015) bài báo khoa học wetenschappelijk artikel mokslinis straipsnis scienca artikolo
p:P577
wds:Q35264283-FEEBEE8C-8B16-42B9-ADC7-7738D5CF5197
wdt:P577
2015-02-10T00:00:00Z
p:P407
wds:Q35264283-A533D26B-1D54-4245-B310-F129E645A69E
wdt:P407
wd:Q1860
p:P2860
wds:Q35264283-9AD52339-54C3-45D3-9811-DF4E13AAA404 wds:Q35264283-9C3CF8CD-632F-470C-AEA2-60D3281B9A98 wds:Q35264283-3818A9EF-6905-4F84-A0A6-EB7B89322794 wds:Q35264283-39C105F1-EE7D-412E-8037-7E95E5A7DFAA wds:Q35264283-3F82195E-976A-4732-8560-1BAA8FF27BE5 wds:Q35264283-4422D826-65B3-4EEE-9E71-1179B229110C wds:Q35264283-57CC0385-9D3F-4866-81AD-5116C7BA9921 wds:Q35264283-5D3E376F-C7DB-435D-8BBA-DD9F6A362359 wds:Q35264283-61F8B2C9-0ED8-4CA7-8F0D-5EC2C532480C wds:Q35264283-673A8E20-6515-465A-B1CD-A083F768DE8D wds:Q35264283-6AD37045-32C1-45D7-9597-10D4916F0BE0 wds:Q35264283-057C931D-15A0-4924-B67D-678B630DC63C wds:Q35264283-06A3E672-E6C8-428A-8A8D-05E38955EA2D wds:Q35264283-0C24C4C0-6EFE-45C3-A8C8-237A36B6D2AB wds:Q35264283-12993E65-4F50-48C7-85F6-F956E06EE91D wds:Q35264283-199297DC-FBBC-4254-BCC3-0E5583529E13 wds:Q35264283-2CF5C6EF-7AE3-4DEB-ACE6-785176750C7C wds:Q35264283-F7ED5B83-F437-47EA-84A0-4586DB95B24C wds:Q35264283-9D34F467-8DBD-46B1-B26F-E4D00B82D9B0 wds:Q35264283-A39CB4C7-2230-46FF-A633-D64468B79B85 wds:Q35264283-A41BC06C-90BE-4528-9694-5AC00D5E6387 wds:Q35264283-AB10D58B-0D32-4854-BE37-4379E6FFFB1B wds:Q35264283-B210F1B7-EE48-4EB5-9FF2-528CE610DB16 wds:Q35264283-B30E19DC-1EA2-4701-9A21-748251CE0307 wds:Q35264283-CF569F4A-4D70-493A-B1BC-C33D5CF0220E wds:Q35264283-D2E7B138-6B21-4566-AB84-BFB83D945A12 wds:Q35264283-D547A6EC-9D01-4E67-A085-F0DFFCDBE976 wds:Q35264283-D9C6C178-AC4E-45D2-A822-9FBB621E12AF wds:Q35264283-7A87DCB9-8CA5-4231-A12F-B303EDDC7C14 wds:Q35264283-7E3B423B-124B-4BAA-9222-0A54F953CE15 wds:Q35264283-7E658B8B-BEC9-4FC7-94A7-B2E991738796 wds:Q35264283-7F98598F-8096-48ED-9E4F-A5C0F233BBBD wds:Q35264283-8AF73ACB-2D21-40FD-A238-24BA88552CF1 wds:Q35264283-8C1D79BC-FCEB-4D7C-B5AD-1AD97509AD2A wds:Q35264283-904020A1-3C8B-4486-862B-BD45A1B8F4C7 wds:Q35264283-9074A06E-9A7C-48D7-8B0B-B1310DF18DCB
wdt:P2860
wd:Q51822227 wd:Q40301251 wd:Q38189509 wd:Q39430345 wd:Q29614601 wd:Q33588191 wd:Q37395388 wd:Q27025411 wd:Q37186494 wd:Q41721009 wd:Q80423904 wd:Q34900634 wd:Q35239088 wd:Q37857507 wd:Q35956440 wd:Q36376782 wd:Q35812402 wd:Q35656974 wd:Q39927915 wd:Q35847701 wd:Q39054011 wd:Q34806737 wd:Q34391423 wd:Q37240714 wd:Q69842539 wd:Q39587868 wd:Q35834849 wd:Q37282661 wd:Q28250203 wd:Q37025950 wd:Q40351465 wd:Q80060434 wd:Q39812008 wd:Q36050883 wd:Q79995600 wd:Q24669579
p:P2093
wds:Q35264283-387D1D57-329D-4933-94E6-6F9D9BE25FBA wds:Q35264283-71DE8787-A84E-4DB0-AEDD-47D66F98DD1B wds:Q35264283-6315B1ED-FFF7-4E46-96B9-D917941EB0A2 wds:Q35264283-7A665385-1D7F-4163-B9A5-90E213884962
wdt:P2093
Haihong Zhong Richard G Thompson Richard Grose Robert E Hollingsworth
rdfs:label
Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer
skos:prefLabel
Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer
schema:name
Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer
p:P50
wds:Q35264283-E90709B3-01EB-486C-BAB4-2991840ABD1F wds:Q35264283-8AA6770F-340E-4C60-A8F2-BF7425A6B039 wds:Q35264283-D065177E-CCE2-493C-8350-23387D5AFA15 wds:Q35264283-BD8B1511-6554-4233-B4B9-2F9CCBF5AD1E wds:Q35264283-21D17D28-F57A-435D-B454-65FC6052C0F6 wds:Q35264283-32E6AEBD-3EAB-4801-BCC0-49C164329B8C wds:Q35264283-1BD7D412-1191-4AEF-8B47-D97417A25BA6
wdt:P50
wd:Q114435679 wd:Q114435680 wd:Q8565319 wd:Q47451431 wd:Q94547720 wd:Q92129143 wd:Q125330286
p:P1476
wds:Q35264283-3265B96F-8495-4BBD-A164-22C84A58DD5B
wdt:P1476
Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer
p:P304
wds:Q35264283-94551F9B-D264-4F5D-B111-DE45CCC8D40A
wdt:P304
1255-1264
p:P31
wds:Q35264283-878EFB56-3D42-48D2-A2AD-2564B2C5CB96
wdt:P31
wd:Q13442814
p:P921
wds:Q35264283-A37D1C8A-66E1-411A-990D-0798CD38FBA6
wdt:P921
wd:Q172341
p:P698
wds:Q35264283-6415E845-CD14-4FB6-BBB8-0B7A76BF3E69
wdtn:P698
n12:25670170
wdt:P698
25670170
p:P1433
wds:Q35264283-925C1ED4-D9EE-4918-AA21-B22000AFC468
wdt:P1433
wd:Q326097
p:P433
wds:Q35264283-43EE887E-9ECA-4EE9-89F1-87E41F591961
p:P478
wds:Q35264283-ABCB5C88-C07F-4A97-BF02-D32E51E82F87
wdt:P433
7
wdt:P478
75
p:P356
wds:Q35264283-59FFDFA3-1D8E-49EC-82E9-CFA1B9DF0035
wdtn:P356
n11:0008-5472.CAN-14-1801
wdt:P356
10.1158/0008-5472.CAN-14-1801
p:P8608
wds:Q35264283-999E6C4C-607B-4FC0-B4F1-DA6324AFDC4A
wdt:P8608
release_o6nx2ypmafcnbdca656v2qgbwe
p:P4510
wds:Q35264283-3DDE0985-AF0A-42E5-A024-008B0BD4B4BC
wdt:P4510
wd:Q1659584
p:P932
wds:Q35264283-B26DE1B1-FF10-4EE5-9327-47755312D80D
wdt:P932
4384986